4-Aryl-5-cyano-2-aminopyrimidines as VEGF-R2 inhibitors: Synthesis and biological evaluation

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 12, 2007, Pages 3266-3270

  Hughes, Terry V ^a   Emanuel, Stuart L ^a   Beck, Amanda K ^a   Wetter, Steven K ^a   Connolly, Peter J ^a   Karnachi, Prabha ^a   Reuman, Michael ^a   Seraj, Jabed ^a   Fuentes Pesquera, Angel R ^a   Gruninger, Robert H ^a   Middleton, Steven A ^a   Lin, Ronghui ^a   Davis, Jeremy M ^b   Moffat, David F C ^b  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b UCB PHARMA   (Belgium)

Author keywords

2 Aminopyrimidines; Angiogenesis; Cancer; KDR; Kinase; Kinase inhibitor; VEGF R2

Indexed keywords

4 (MORPHOLIN 4 YLDIETHYL)PHENYL DERIVATIVE; 5 CYANO 2 AMINOPYRIMIDINE DERIVATIVE; JNJ 17029259; NITRILE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 2 INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; IC 50; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALS; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; MICE; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 34249698235     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.04.021     Document Type: Article

References (15)

1. Aiello L.P., Avery R.L., Arrigg P.G., Keyt B.A., Jampel H.D., Shah S.T., Pasquale L.R., Thieme H., Iwamoto M.A., Park J.E., Nguyen H.V., Aiello L.M., Ferrara N., and Park G.L. New Engl. J. Med. (1994) 1480
2. Adamis A.P., Miller J.W., Bernal M.T., D'Amico D.J., Folkman J., Yeo T.K., and Yeo K.T. Am. J. Opthamol. (1994) 445
3. Ozaki H., Seo M.-S., Ozaki K., Yamada H., Yamada E., Okamoto N., Hofmann F., Wood J.M., and Campochiaro P.A. Am. J. Pathol. (2000) 697
4. Emanuel S., Gruninger R.H., Fuentes-Pesquera A., Connolly P.J., Seamon J.A., Hazel S., Tominovich R., Hollister B., Napier C., D'Andrea M.R., Reuman M., Bignan G., Tuman R., Johnson D., Moffatt D., Batchelor M., Foley A., O'Connell J., Allen R., Perry M., Jolliffe L., and Middleton S.A. Mol. Pharmacol. 66 (2004) 635
5. Batchelor, M. J.; Moffat, D. F. C.; Davis, J. M.; Hutchings, M. C. U.S. Patent 6,579,983, 2003.
6. Glide 3.5, Schrodinger, New York, 2005.
7. Friesner R.A., Banks J.L., Murphy R.B., Halgren T.A., Klicic J.J., Mainz D.T., Repasky M.P., Knoll E.H., Shaw D.E., Shelley M., Perry J.K., Francis P., and Shenkin P.S. J. Med. Chem. (2004) 1739
8. Doe J.S., Smith J.J., and Roe R.P. J. Am. Chem. Soc. (1968) 8234
9. No scaling factors were applied to the van der Waals radii. Default settings were used for all the remaining parameters. The top 20 poses based on Glidescore were energy-minimized with Macromodel using both the OPLS-AA, and the refined poses reranked using Glidescore.
10. Liu M., Luo M., Mozdziesz D.E., and Sartorelli A.C. Nucleosides Nucleotides (2005) 45
11. Details of the synthetic transformation of 11-14 will be reported elsewhere.
12. 4
13. Kenyon B.M., Voest E.E., Chen C.C., Folkman J., and D'Amato R.J. Investig. Ophtalmol. Vis. Sci. 37 (1996) 1625
14. Angiogenesis was induced with bFGF in these models because it produced a more robust vascular response than VEGF (data not shown).
15. Hirata A., Ogawa S.-I., Komentani T., Kuwano T., Naito S., Kuwano M., and Ono M. Cancer Res. (2002) 2554